Radioisotopes for medical and industrial use during the 50-year history of the Institute of Nuclear Research

• Autorzy: Mikołajczak R. , Bazaniak Z. , Iller E.
• Konferencja: Proceedings of the Jubilee Symposium for the 50th anniversary of the foundation of the Institute of Nuclear Research "Atomic Science in the XXI Century" June 16, 2005, Warsaw, Poland
• Języki publikacji: EN

Abstrakty

EN

The paper summarises the 50-years long history of the development of research programmes related to the practical applications of radionuclides in various fields of the Polish economy. The changing trends of interest of the potential users are reflected in the research and development activities of the Radioisotope Centre POLATOM. In the 1960's and 1970's the main areas of activity were focused on the sealed sources and radiolabelled compounds for the investigation of industrial processes. The introduction to the routine practice of the RIA and the IRMA kits for hormonal in vitro diagnostics in the 70-ties and 80-ties resulted in the general availability of this diagnostic technique in Poland. The number of radioisotopes having the required radiation type, energy and half-life is steadily increasing due to the progress in irradiation facilities and in chemical separation processes. The need for modern radiopharmaceuticals, more specific and providing higher diagnostic and therapeutic potential as an alternative to other medical modalities is reflected in the research programmes carried out and implemented currently at the Radioisotope Centre POLATOM.

Słowa kluczowe

EN

radiopharmaceuticals; isotope application; sealed sources; radiotherapy; brachytherapy

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2005
• Tom: Vol. 50,suppl.3
• Strony: 83--87
• Opis fizyczny: Bibliogr. 26 poz., rys.

Twórcy

autor

Mikołajczak R.

• Radioisotope Centre POLATOM, 05-400 Otwock-Świerk, Poland, Tel.: [phone], Fax:[phone]

autor

Bazaniak Z.

• Radioisotope Centre POLATOM, 05-400 Otwock-Świerk, Poland, Tel.: [phone], Fax:[phone]

autor

Iller E.

• Radioisotope Centre POLATOM, 05-400 Otwock-Świerk, Poland, Tel.: [phone], Fax:[phone]

Bibliografia

• 1. Byszewska-Szpocińska E (2001) Compounds radiolabelled with 125I applicable in medical radioimmunodiagnostics in vitro. Postępy Techniki Jądrowej 44;2:19−23 (in Polish)
• 2. Byszewska-Szpocińska E, Karczmarczyk U, Mikołajczak R (2004) Recombinant hTSH radiolabelled with technetium-99m a new promising radiopharmaceutical for diagnosis of metastases in differentiated thyroid cancer − preliminary studies (abstract). Nuclear Medicine Review 7:99
• 3. Byszewska-Szpocińska E, Łukaszewski M, Baranowska A (1993) The new “coated tubes” radioimmunodiagnostic kits for determination of tumor markers: alphafetoprotein (AFP) and carcinoembryonic antigen (CEA) in human serum. Immunoassay 3;2:238−242
• 4. Byszewska-Szpocińska E, Markiewicz A (2002) Investigations on preparation of 125-I-gastrine and 125-I-minigastrine for application in medical diagnostics. Raporty IChTJ Seria A 1:172−179 (in Polish)
• 5. Cieszykowska I, Piasecki A, Mielcarski M (2005) An approach for the preparation of iodine-125 seed-type sources. Nukleonika 50;1:17−22
• 6. Cieszykowska I, Piasecki A, Mikołajczak R, Mielcarski M (2003) Development of radioactive sealed sources for use in intravascular therapy. In: Technical report of the 2nd Research Co-ordination Meeting on Development of Radioactive Sources for Emerging Therapeutic and Industrial Application, 20−24 October 2003. IAEA, Vienna, pp 45−53
• 7. Deptuła Cz, Chmielowski K, Kempisty T et al. (1996) Method of preparation and application of strontium chloride-89SrCl2 for palliative treatment of painful bone metastases. Part I. Production method of strontium −89Sr chloride. Problemy Medycyny Nuklearnej 10;19:161–168
• 8. Deptuła Cz, Kempisty T, Markiewicz A et al. (1997) Quality control methods of strontium chloride 89SrCl2, radiopharmaceutical for palliative treatment of bone metastases. In: Proc of 2nd Int Conf of Isotopes, Sydney, Australia, pp 196−199
• 9. Górska-Chrząstek M, Grzelak P, Bieńkiewicz M et al. (2004) Assessment of clinical usefulness of 131I-alphamethyl-tyrosine and fused SPECT/MRI imaging for diagnostics of recurrent cerebral gliomas. Nuclear Medicine Review 7:135−141
• 10. Hubalewska A, Fröss K, Mikołajczak R et al. (2004) 99mTcEDDA/HYNIC-TATE scintigraphy: a method for diagnosis and staging of NET? In: MEDIMOND S.r.I, E831C0871, pp 1483−1487
• 11. Karczmarczyk U, Markiewicz A, Mikołajczak R et al. (2004) 99mTc human IgG radiolabelled by HYNIC. Biodistribution and scintigraphy of experimentally induced inflammatory lesions in animal model. Nuclear Medicine Review 7:107−112
• 12. Mielcarski M, Iwińska H (1980) Radioactive enamels containing plutonium-239. Isotopenpraxis 16:26−28
• 13. Mielcarski M, Molenda E (1987) Glazy enamels as fixing agents for preparing alpha radiation sources. In: High tech ceramics. Materials Science Monographs, vol. 38B. Elsevier Sci Publ Co., Amsterdam-New York, pp 2911−2916
• 14. Mielcarski M, Poniński M, Malkiewicz S (1975) Sorption of plutonium on anodized aluminium. Nukleonika 20:931−935
• 15. Mielcarski M, Puchalska I (2002) Deposition of Ru-106 and I-125 on silver by internal electrolysis. Nukleonika 47;2:83−86
• 16. Mikołajczak R, Markiewicz A, Deptuła Cz et al. (2001) 99mTc labelled peptides for imaging of peripheral receptors. In: 99mTc labelled peptides for imaging of peripheral receptors. Final report of co-ordinated research project 1995−1999. IAEA TECDOC-1214. IAEA, Vienna, pp 93−101
• 17. Mikołajczak R, Parus JL, Pawlak D, Zakrzewska E, Michalak W, Sasinowska I (2003) Reactor produced 177Lu of specific activity and purity suitable for medical applications. J Radioanal Nucl Chem 257:53–57
• 18. Mirowski M, Wiercioch R, Balcerczak E et al. (2001) Uptake of radiolabeled herceptin by experimental mouse mammary carcinomas (abstract). Eur J Nucl Med 28;8:1193
• 19. Mirowski M, Wiercioch R, Janecka A et al. (2004) Uptake of radiolabelled morphiceptin and its analog by experimental mammary adenocarcinoma: in vitro and in vivo studies. Nuclear Medicine and Biology 31:451−457
• 20. Molenda E, Mielcarski M (1998) Electrodeposition of 106Ru and 241Am and derived information on preparing sealed radiation sources. J Radioanal Nucl Chem 238:159−162
• 21. Parus JL, Pawlak D, Mikołajczak R, Sasinowska I (2004) Determination of elemental and radionuclidic impurities in 177Lu used for labelling of radiopharmaceuticals. J Radioanal Nucl Chem 261:469−472
• 22. Płachcińska A, Mikołajczak R, Maecke HR et al. (2003) Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics – a preliminary communication. Eur J Nucl Med 30;10:1402–1406
• 23. Płachcińska A, Mikołajczak R, Maecke HR et al. (2004) Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics – a pilot study. Cancer Biother Radiopharm 2;19:261−270
• 24. Puchalska I, Mielcarski M (2003) Seed-less iodine-125 ophthalmic applicators. Appl Radiat Isot 58:15−20
• 25. Puchalska I, Piasecki A, Barcikowski T, Mielcarski M (2002) Ophthalmic applicators of 125I with monolithic radioactive core. Raporty IChTJ Seria A 1:143–149 (in Polish)
• 26. Welling MM, Korsak A, Górska B et al. (2005) Kit with technetium-99m labeled antimicrobial peptide UBI 29-41 for specific infection detection. J Label Compd Radiopharm 48:683−691